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Introduction
Preeclampsia is defined as being a pregnancy specif-
ic syndrome of elevated blood pressure (>140/90 mmHg)
and proteinuria of >100 mg/dl by urine analysis or >300mg
in a 24-hour urine collection, after 20 weeks of gestation.1
The disorder, almost 2000 years ago, was called
eclampsia reflecting the description given by Celsus as
pregnant women with seizures, that abated with delivery
and thus, for 2000 years this disorder was considered a
pregnancy-specific seizure disorder.2 In the late 1800s, the
association of initial proteinuria and later increased blood
pressure with eclampsia was noted. Additionally, the fact
that increased blood pressure and urinary protein antedated
the seizures2, the term preeclampsia was introduced.
Preeclampsia is one of the major causes of maternal
and fetal morbidity and mortality3 and accounts for the
majority of referrals to obstetric day care units4 and hospi-
tal admissions.5 It has been reported that the greatest impact
is seen in developing countries where it accounts for 20-
80% of the strikingly increased maternal mortality.6
However, even in developed countries the impact is heavy,
primarily on the fetus, where perinatal mortality is increased
5-fold and indicated preterm deliveries for preeclampsia
account for 15% of preterm births.6 The incidence of
preeclampsia is about 5-7% of all pregnancies.1
Preeclampsia is more common in a primigravida; the risk
reducing to >50% in the subsequent pregnancies.7 The
established risk factors for preeclampsia are obesity, black
race, chronic hypertension, diabetes or insulin resistance,
collagen vascular disease, thrombophilias, increased circu-
lating testosterone, multiple gestations and previous
preeclampsia.8 Most researches have focused on maternal
contribution to the disease however, little is known about
the paternal contribution to this disease. A study conducted
to assess the paternal role in particular, provided evidence of
both paternal and maternal components of the predisposi-
tion to preeclampsia, supporting the theory that genetic con-
tributions from both parents are important in the develop-
ment of the disorder.9 
The purpose of this review article is to discuss the
means by which preeclampsia can be potentially predicted
even before the disease can become clinically diagnosable.
Prior knowledge about the preeclampsia and the application
of appropriate prenatal care and management before the dis-
ease progresses to become life threatening can largely elim-
inate maternal mortality.6
Pathophysiology of Preeclampsia
Preeclampsia has long been a disease with an
unknown etiology. Various studies have been conducted to
decipher the factors involved and this has lead to the devel-
opment of a few theories. From history, it comes that uter-
ine distension and even fetus have been thought to be the
probable contributors. Since it was found that preeclampsia
can occur with abdominal ectopic pregnancies without
increased uterine size and is more common in pregnancies
without a fetus [hydatidiform mole]10, this eliminated these
two possibilities. The placenta is necessary for preeclamp-
sia but all pregnant women have placentas and only 5%
become preeclamptic.11
The trend of thought changed when Page E.W. many
years ago suggested that the important placental feature in
preeclampsia was poor perfusion.12 It was presumed that
with the large placenta the normal vasculature of the placen-
tal site is inadequate to perfuse the very large organ and rel-
ative placental hypoperfusion is present.13
Preeclampsia now is thought to be a 2-stage disease.8
Stage 1 is characterized by a reduction in perfusion. Stage 2
is the maternal syndrome. A predominant pathophysiologi-
cal feature is reduced perfusion of virtually all organs that is
due to vasoconstriction, micro thrombi formation and
reduced circulating plasma volume.3 The endovascular tro-
phoblastic invasion that occurs in normal pregnancies is
absent in the placenta of preeclamptic women and therefore
the blood flow is reduced, leaving the placenta ischemic.8
The vasoconstriction is secondary to an increased sensitivi-
ty of the vasculature to any pressor agent.3 Activation of the
coagulation cascade produces micro thrombi.3 The reduced
plasma volume, reflecting an endothelial leak with fluid loss
from the intravascular compartment, further compromises
perfusion.3 These abnormalities precede clinically evident
disease by weeks to months and have led to the suggestion
that a primary target in preeclampsia is the vascular
endothelium.
The role of various circulating factors including vas-
cular endothelial growth factor (VEGF), placental growth
factor (PlGF), fms-like tyrosine kinase 1 (Flt1), agonistic
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agonistic antibodies against angiotensin 1 receptors
and asymmetric dimethylarginine has also  been studied.
These factors might interfere with angiogenesis, engage
angiotensin II signaling, and directly impair endothelial
function.14
Need to discover methods for predicting Preeclampsia
Preeclampsia being a substantial cause of maternal
and fetal morbidity and mortality has drawn the attention of
researchers since long. There have been several attempts to
discover methods that may help in early diagnosis of the
disease. The need of the discovery of such screening meth-
ods has also been emphasized by the discovery of various
other facts, one of which is that children born to preeclamp-
tic mothers may suffer from various diseases like diabetes
type 1.15 Clinical screening may fail to detect the disease
before severe complications have developed.16 The require-
ments for an effective screening test are that it needs to
identify women at risk early in pregnancy so that care and
outcome can be modified.
Biochemical markers for Preeclampsia
The objective in most of the researches conducted in
various parts of the world has been the discovery of bio-
chemical markers because these new plasma/serum bio-
chemical markers might be helpful in identifying subjects at
increased risk for developing preeclampsia. A couple of
these attempts have been fruitful however; many queries
need to be answered yet.  
Inhibin A and Activin A levels
Inhibins and activins are glycoprotein hormones
belonging to the transforming growth factor βsuper family17
produced by the feto-placental unit in pregnancy.18
Concentrations of circulating dimeric inhibin A rise in early
pregnancy, fall after 12 weeks of gestation, and remain low
until 24 weeks.19 Thereafter, concentrations increase gradu-
ally but with a marked rise in the third trimester.19
Circulating concentrations of activin A are similar during
the first and second trimester and rise progressively in the
third trimester with a steep increase at term.20 It has been
shown that maternal serum concentrations of inhibin A and
activin A are 10-fold higher in women with severe
preeclampsia compared to gestational age-matched con-
trols.21 A study conducted to investigate the time course of
the changes in relation to the onset of the maternal syn-
drome and if their measurement could be useful for clinical
prediction particularly in relation to early onset disease,
showed that serum inhibin A and activin A concentrations
increase before the onset of preeclampsia at gestational ages
that depend on when preeclampsia develops.17 It is not
known why inhibin A and activin A are increased and
whether they contribute to the etiology or the compensatory
mechanism of the disease. A probable explanation for the
concomitant increases in activin A and inhibin A may be
that activin A stimulates production of human chorionic
gonadotrophin (HCG) by first-trimester trophoblast22 and
HCG increases secretion of inhibin A production by cul-
tured placental cells.23 However, activin A may be produced
by circulating inflammatory cells rather than or as well as,
from trophoblast.24
Leptin levels
Leptin, the product of the ob gene, is a hormone that
is produced mostly in adipose cells.25 It is also produced in
the placenta and may affect a number of processes in this
organ, including angiogenesis, growth and immunomodula-
tion.26 It has been suggested that leptin may be involved in
the pathogenesis of preeclampsia.26 Many studies have
reported high maternal leptin concentrations in the second
trimester of pregnancy in women with preeclampsia.27
However, serum leptin concentrations in the early part of
pregnancy did not differ between the preeclamptic and non-
preeclamptic women.28 This finding undermines the predic-
tive value of leptin levels in the early stages of pregnancy. 
Insulin-like growth factor-1 Levels
Insulin-like growth factor-1 (IGF-1) is a hormone
that may be involved in both normal and abnormal fetal
growth.29 During circulation it is bound to 6 proteins, the
IGFBPs that regulate IGF-1 action by inhibiting or enhanc-
ing its effects.30 Seventy-five percent of IGF-1 is a high
molecular mass ternary complex formed by IGF-1, IGFBP-
3, and an acid-labile subunit; 24% is bound to IGFBP-3 and
remaining 1% circulates as free IGF-1.31
This hormone stimulates the renal and placental
1,25-dihydroxyvitamin D synthesis.32 During normal preg-
nancy birth weight is positively correlated with maternal
and fetal IGF-1 and IGFBP-3A, and negatively correlated
with maternal and fetal IGFBP-1concentrations.33 It has
been found that during preeclampsia the maternal IGF con-
centrations are lower compared with those in normal preg-
nancy.34 
Maternal Plasma Fetal DNA Levels
It has been shown that there is a 5-fold increase in
circulating fetal DNA concentrations in the plasma of
women with established preeclampsia compared with con-
trol pregnant subjects.35 A further study aimed at testing
that whether the abnormal increase in circulating fetal DNA
concentrations can be detected in susceptible subjects
before the onset of the clinical disease resulted in affirma-
tive evidence.36 In that study, plasma samples were assayed
for circulating fetal DNA, using the SRY gene on the Y
chromosome as a marker. Circulating fetal DNA was detect-
ed in all subjects carrying male fetuses in both the
detected in all subjects carrying male fetuses in both
the preeclamptic and control groups. The possible pathway
for maternal plasma fetal DNA increase in preeclampsia is
likely to be increased liberation of fetal DNA into the mater-
nal circulation.36 This increase could be secondary to an
increased entry of fetal cells, such as trophoblasts37 and ery-
throblasts38, into the maternal circulation or the fetal DNA
could liberate directly from dying cells in the placenta and
a confirmation to this comes from the demonstration of
widespread apoptosis in cytotrophoblasts obtained from the
placental beds of preeclamptic pregnancies.39 Nevertheless,
this is a new marker that may help in predicting preeclamp-
sia.
Comments
As discussed, since preeclampsia is associated with
significant morbidity and mortality for both mother and
fetus, it is a desirable objective that the disorder should be
diagnosed as early as possible, preferably before the onset
of complications. The aim of the early diagnosis is that the
therapeutic interventions can be modified and tailor-made
accordingly. However, the effective means of prediction of
the disease are still lacking. In the context of the pathophys-
iology of preeclampsia, the levels of biochemical markers
are considered as the potential candidates for predicting the
development of disease at later stages. The requirements of
an ideal marker for the prediction of preeclampsia would be
that it should be highly sensitive and specific. Besides it
should be able to identify the women at risk very early in the
pregnancy.
As far as various biochemical markers with a poten-
tially predictive value for preeclampsia are concerned, none
has shown to be universally acceptable and reliable. For
example, it has been seen that there is an overlap in the fetal
DNA concentrations between the preeclamptic and control
groups.36 This implies that a relatively low sensitivity and
specificity would result if maternal plasma fetal DNA meas-
urement is used as the sole predictor for preeclampsia.
However, the statistical analysis revealed that the best dis-
crimination between the preeclamptic and control groups
was obtained at a fetal DNA concentration of 33.5 genome-
equivalents/mL.36 Work needs to be done to explore the use
of fetal DNA markers outside the Y chromosome so that
this type of analysis can be extended to pregnant women
carrying female fetuses.
Similarly, serum leptin levels have been observed to
be raised in preeclamptic women, albeit in the second
trimester of pregnancy.27 In the early stages, no difference
in the concentration of this hormone was noted between the
normal and would be preeclamptic women.28 These results
eclipse the predictive value of leptin for high risk groups.
However, inhibin A, which has already proved to be
useful in screening for fetal karyotype abnormalities, has
been shown to be a potentially promising predictive bio-
chemical marker for the diagnosis of early placental abnor-
mality. This hormone has been shown to be raised in a sig-
nificant number but not all of cases of preeclampsia before
the onset of complications.21 However, it remains to be seen
whether inhibin A concentrations that are measured
prospectively in early pregnancy are useful predictors of
preeclampsia. Further studies need to be conducted to con-
firm the results and to evaluate the predictive value of serum
inhibin A concentration early in pregnancy, and the efficien-
cy of prediction may be increased by the consideration of
other risk markers, such as pregnancy-associated plasma
protein levels.40, or first-trimester Doppler studies of the
uterine arteries.41 It would be important to assess whether
the measurement of other indices combined with inhibin A
can produce a test with greater sensitivity for preeclampsia
as occurs with triple or quadruple blood tests for Down's
syndrome. This would open up new possibilities for the test-
ing of preventive methods and the trials of treatments for
this pregnancy-specific syndrome.
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